B Braun Singapore is acquiring 26% in New Delhi based Ahlcon Parenterals (India) Ltd through an open offer.
B Braun will acquire 1,872,039 equity shares from the shareholders of Ahlcon Parenterals at a price of R460 per share.
Deutsche Equities India Pvt Ltd has been appointed as Manager to the Open Offer.
According to the filing on BSE, the acquisition is proposed to be in range of 49% to 70.49%.
Established in 1992 by Bikramjit Ahluwalia, Ahlcon Parenterals manufactures life saving Intravenous Fluids and medical disposals.
As on Dec 2011, promoters and promoter group together old 70.95% stake in the company.
It undertakes manufacturing of Small Volume Parenterals (SVPs) such as Eye/Ear drops, Injectables, antibiotics, respiratory products etc and Large Volume Parenterals (LVPs) such as IVFs including Glucose, Saline water at its single manufacturing facility located in Bhiwadi, Rajasthan.
The company has an installed capacity of 30 million bottles per annum for LVP; 150 million vials of Eye drops and Injections both in transparent and white opaque packs as SVP.
Performance on BSE
It exports its products to the CIS countries, including Russia, Ukraine, and Kazakhstan; and the African, GCC, and eastern European countries, as well as to south east Asia.
B. Braun Singapore provides products and services for general medical treatment and comprehensive therapy concepts in hospitals, surgery, general practice, home care and dialysis in Singapore.